Close
RNS Number : 0502E
ValiRx PLC
15 October 2018
 

 

 

VALIRX PLC

("ValiRx" or the "Company")

 

 VAL401 RESULTS TO SHORTLY BE AVAILABLE ON CLINICALTRIALS.GOV

 

London, UK., 15 October 2018: ValiRx Plc (AIM: VAL), the clinical stage biotechnology company, is pleased to advise that the results from the Phase II trial of VAL401, the anti-cancer compound developed by ValiSeek, the joint venture between ValiRx and Tangent Reprofiling Limited, for late stage non-small cell lung adenocarcinoma, have been accepted for inclusion in the publicly accessible database, ClinicalTrials.gov (NCT02875340), and will shortly become available.

 

 

Dr Suzy Dilly, CEO of ValiSeek, commented: "The acceptance of the results into the independent external database satisfies the requirement to make publicly available all data from clinical trials, providing a statement of numerical listing of data.  Although, along with the submission of the Clinical Study Report to the Ministry of Health in Tbilisi, this concludes our formal obligations on trial reporting, we are also in the process of publication through peer-reviewed industry journals, which will provide interpretation of these listed results.  I look forward to announcing the release of these further publications in due course."

 

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

 

*** ENDS ***

 

For more information, please contact:

ValiRx plc

Tel: +44 (0) 20 3008 4416

www.valirx.com

Dr Satu Vainikka, Chief Executive

Tel: +44 (0) 20 3008 4416

Tarquin Edwards, Head of Communications.

Tel: +44 (0) 7879 458 364

tarquin.edwards@valirx.com



Cairn Financial Advisers LLP (Nominated Adviser)

Liam Murray/Jo Turner/Richard Nash

Tel: +44 (0) 20 7213 0880



Novum Securities Limited (Broker)

Colin Rowbury

Tel: +44 (0) 20 7399 9400

 

 

Notes for Editors

 

About ValiRx

ValiRx is a biotechnology oncology focused company specialising in developing novel treatments for cancer and associated biomarkers. It aims to make a significant contribution in "precision" medicine and science, namely to engineer a breakthrough into human health and well-being, through the early detection of cancer and its therapeutic intervention.

 

The Company's business model focuses on out-licensing therapeutic candidates early in the development process. By aiming for early-stage value creation, the company reduces risk considerably while increasing the potential for realising value. The group is already in licensing discussions with major players in the oncology field.

 

ValiRx's two classes of drugs in development, which each have the potential for meeting hitherto unmet medical needs by existing methods, have worldwide patent filings and agreed commercial rights.   They originate or derive from Word class institutions, such as Cancer Research UK and Imperial College. 

 

Until recently, cancer treatments relied on non-specific agents, such as chemotherapy.  With the development of target-based agents, primed to attack cancer cells only, less toxic and more effective treatments are now possible. New drugs in this group-such as those in ValiRx's pipeline-promise to greatly improve outcomes for cancer patients.

 

The Company listed on the AIM Market of the London Stock Exchange in October 2006 and trades under the ticker symbol: VAL


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
MSCMABLTMBABMPP